Title: The gut microbiome and early-life growth in a population with high prevalence of stunting

Authors: Ruairi C. Robertson^{1†}, Thaddeus J. Edens^{2†,} Lynnea Carr^{3†}, Kuda Mutasa⁴, Ceri Evans^{1,4}, Ethan K. Gough⁵, Hyun Min Geum⁶, Iman Baharmand⁶, Sandeep K. Gill⁶, Robert Ntozini⁴, Laura E Smith^{4,7}, Bernard Chasekwa⁴, Florence D. Majo⁴, Naume V. Tavengwa⁴, Batsirai Mutasa⁴, Freddy Francis⁸, Joice Tome⁴, Rebecca J. Stoltzfus⁹, Jean H. Humphrey⁵, Andrew J. Prendergast^{1,4,5}, Amee R. Manges^{6,10}, and the SHINE Trial Team¹¹

Affiliations:

¹Blizard Institute, Queen Mary University of London, London, UK

²Devil's Staircase Consulting, West Vancouver, British Columbia, Canada

³Department of Microbiology and Immunology, University of British Columbia, Canada

⁴Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe

⁵Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

⁶School of Population and Public Health, University of British Columbia, Vancouver, Canada

⁷Department of Population Medicine and Diagnostics, Cornell University, Ithaca, NY, USA ⁸Department of Experimental Medicine, University of British Columbia, Canada ⁹Goshen College, Goshen, Indiana, USA

¹⁰British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada ¹¹Members of the SHINE Trial team who are not named authors are listed in <u>https://academic.oup.com/cid/article/61/suppl 7/S685/358186</u>

[†] These authors contributed equally to this work

***Corresponding author:** Amee R. Manges, MPH, PhD, School of Population and Public Health, University of British Columbia, 314-2206 East Mall, Vancouver, BC Canada, amee.manges@ubc.ca

One sentence summary: The gut microbiome of rural Zimbabwean infants undergoes programmed maturation that is unresponsive to sanitation and nutrition interventions but is comprehensively modified by maternal HIV infection and can moderately predict linear growth.

1 ABSTRACT

2

Stunting affects one-in-five children globally and is associated with greater infectious 3 morbidity, mortality and neurodevelopmental deficits. Recent evidence suggests that the 4 early-life gut microbiome affects child growth through immune, metabolic and endocrine 5 pathways, and microbiome perturbations may contribute to undernutrition. We examined 6 early-life fecal microbiome composition and function in 875 stool samples collected 7 longitudinally in 335 children from 1-18 months of age in rural Zimbabwe, from a cluster-8 randomized trial of improved water, sanitation, and hygiene (WASH), and improved infant 9 and young child feeding (IYCF). Using whole metagenome shotgun sequencing, we 10 11 examined the effect of the interventions, in addition to environmental or host factors including maternal HIV infection, on the succession of the early-life gut microbiome, and 12 employed extreme gradient boosting machines (XGBoost) to model microbiome 13 maturation and to predict child growth. WASH and IYCF interventions had little impact on 14 15 the fecal microbiome, however children who were HIV-exposed but uninfected exhibited over-diversification and over-maturity of the early-life gut microbiome in addition to 16 reduced abundance of Bifidobacteria species. Taxonomic microbiome features were 17 poorly predictive of linear and ponderal growth, however functional metagenomic 18 19 features, particularly B-vitamin and nucleotide biosynthesis pathways, moderately predicted both attained linear and ponderal growth and growth velocity. We find that the 20 succession of the gut microbiome in a population at risk of stunting is unresponsive to 21 WASH and IYCF interventions, but is strongly associated with maternal HIV infection. 22 which may contribute to deficits in growth. New approaches targeting the gut microbiome 23 in early childhood may complement efforts to combat child undernutrition. 24

1 Main Text:

2

3 INTRODUCTION

Stunting, or linear growth failure, is a form of chronic undernutrition that affects 22% of 4 children under 5 years of age worldwide (1, 2). Stunting is associated with infectious 5 6 morbidity, reduced childhood survival and impaired cognitive development (3). The lifelong impacts of poor growth contribute to an intergenerational cycle of stunting and 7 impaired development, lower educational attainment, and reduced adult economic 8 9 productivity (4). Nutritional interventions, however, only reduce stunting by approximately 12% (5), suggesting that other pathophysiological mechanisms contribute to chronic 10 undernutrition, which may inform new therapeutic strategies. 11

12

The determinants of stunting and other forms of child undernutrition are complex and 13 14 include a myriad of biological, environmental and social factors including breastfeeding and complementary feeding practices, household water, sanitation and hygiene (WASH) 15 practices, birthweight, maternal HIV status, maternal anthropometry and maternal 16 17 education. However, growing evidence suggests that a subclinical disorder of the small intestine, termed environmental enteric dysfunction (EED), may play a role in impaired 18 19 child growth (6). EED is characterized by blunted intestinal villi, increased gut 20 permeability, and microbial translocation into the circulatory system resulting in both local 21 and chronic inflammation and nutrient malabsorption (7, 8). It is hypothesized that high 22 enteric pathogen carriage, as seen in poor-hygiene, low-resource settings, contributes to 23 the pathophysiology of EED (9-11); however, interventions to improve WASH and reduce

the pathogen burden in children have failed to demonstrate improvements in linear growth
(12). Additionally, both enteric pathogen load and common biomarkers of EED are not
consistently associated with linear growth in different geographical cohorts (13-16),
suggesting that the pathway linking microbial exposures, impaired gut function and earlylife growth remains to be fully elucidated.

6

In addition to research investigating the influence of diarrheal pathogens on child 7 undernutrition and EED, emerging evidence supports the role of the commensal gut 8 9 microorganisms in mediating child growth. Healthy-growing children exhibit a patterned ecological assembly of the gut microbiome through the first 2 years of life, which is defined 10 by delivery mode, breastfeeding and complementary feeding practices (17). This 11 microbial succession impacts a number of metabolic, immune and endocrine pathways 12 in early life that contribute to early-life growth and development (18). Disturbances to this 13 14 normal microbiome maturation therefore may impair these critical growth and developmental pathways. Immaturity of the early-life gut microbiome is associated with 15 severe acute malnutrition (19), whilst reduced microbiome diversity is associated with 16 17 higher risk of future diarrheal episodes (20). Indeed, a 'malnourished' early-life gut microbiome can recapitulate phenotypes of faltering growth and EED when transplanted 18 19 into germ-free mice and pigs (21, 22). Furthermore, nutritional interventions designed to 20 specifically target the impaired gut microbiome in acute malnutrition in both animal studies 21 and small-scale human trials have recently demonstrated a positive effect on ponderal 22 growth (23, 24), but not on linear growth.

23

Microbiome differences that may contribute to stunting are likely influenced by a number 1 of environmental factors including household WASH, infant feeding practices and 2 maternal HIV infection. To date, little research has investigated the effect of improved 3 WASH or infant feeding interventions on the assembly of the infant gut microbiome in low 4 resources settings. However, recent data show that children who are HIV-exposed but 5 6 uninfected (CHEU), consume breast-milk with an altered oligosaccharide composition from their mothers (25), and may be exposed to abnormal microbiome profiles from their 7 mothers, which have been reported in people living with HIV (26, 27). CHEU also receive 8 9 prophylactic antibiotics, to prevent infectious morbidity associated with HIV exposure. Each of these exposures may influence the seeding and succession of the gut 10 microbiome in CHEU (28, 29), which may contribute to the high prevalence of stunting 11 observed in CHEU (30). Evidence of the effect of other early-life environmental exposures 12 on the assembly of the infant gut microbiome in low resources settings is scarce but may 13 14 provide insights into the influence of microbial and microbiota-modifying exposures on child growth in the context of undernutrition. 15

16

17 Previous cross-sectional data from sub-Saharan Africa hypothesized that decompartmentalization of the gastrointestinal tract occurs in stunted children, as 18 19 demonstrated by the overgrowth of oropharyngeal bacterial taxa in the intestine (31), 20 whilst a handful of other cross-sectional studies report variations in gut microbiota 21 composition in stunted children that are inconsistent across geographical settings (32-22 34). We previously reported that the maternal gut microbiome can predict birthweight and 23 neonatal growth in rural Zimbabwe (27). However, there are few studies mapping the

compositional and functional maturation of the gut microbiome throughout early
 childhood, accounting for feeding, WASH, maternal HIV infection and other environmental
 exposures, in populations from low-resource settings and at high risk of stunting.

4

Here, we characterize the succession and maturation of the fecal microbiome from 1 to 5 6 18 months of age in 335 children from rural Zimbabwe who were enrolled in the Sanitation, Hygiene, Infant Nutrition Efficacy (SHINE) Trial (35). We explore gut 7 microbiome maturation and examine the influence of randomized WASH and nutrition 8 9 interventions and maternal HIV infection. Using compositional and functional metagenomic data as well as extensive epidemiological information, we use machine 10 learning to test the ability of the early-life gut microbiome to predict both attained linear 11 and ponderal growth and growth velocity through the first 18 months of life. 12

13

14

15 **RESULTS**

16 Sub-study population characteristics

The fecal microbiota was characterized in 875 fecal samples from 335 children from 1-18 months of age (Fig. S1). A mean (SD) of 2.6 (1.3) samples were analysed per child. The children in the microbiome sub-study largely resembled the population of all live-born infants in the overall SHINE trial cohort (Table S1), however, the microbiome sub-study included a larger number of children who were born to women living with HIV (29.6%) compared to the whole SHINE cohort (15.6%), due to the deliberate over-sampling of HIV-positive mothers and their infants. In addition, the microbiome sub-study included

infants with slightly older mothers and longer gestational ages. The majority of infants
were born by vaginal delivery (94.5%) in an institution (89.9%) and were exclusively
breastfed (91% at 3 months). Prevalence of stunting (LAZ <-2) varied from 18-34% across
study time-points.

5

6 Metagenome sequencing performance

Overall, 875 unique infant-visit whole metagenome sequencing datasets were used. On 7 average, 12 million \pm 4.2 million guality-filtered read pairs were generated per sample. 8 9 Sixteen negative controls produced a mean of 655 quality-filtered reads (range = 149 to 1,425; SD = 456). The median percent of human reads detected was 0.05% but ranged 10 widely by age group and decreased over time (Fig. S2a). The median percent un-11 annotatable reads detected in each sample was 58.6% and increased over time (Fig. 12 S2b). Thirty-six samples were subject to repeated extraction and metagenome 13 14 sequencing to assess technical variation. These samples originated from 4 unique children, each with 3 visit samples, where each visit sample was extracted and 15 sequenced in 3 replicates. Principal coordinates analysis (PCoA) of Bray-Curtis distances 16 17 and phylum-level relative abundances revealed little variation between replicates (Fig. S2c-d). 18

19

20 Succession of gut microbiome composition in early childhood

After prevalence and relative abundance threshold filtering, 161 annotated bacterial species were identified. Seven Eukaryotic and 4 Archaeal species were detected in a small proportion of samples, but these did not meet the prevalence thresholds (Table S2).

Bifidobacterium longum was the predominant species at all time-points up to 12 months 1 of age. Four other Bifidobacteria speces (B. breve, B. bifidum, B. pseudocatenulatum, 2 and B. kashiwanohense). Escherichia coli. Bacteroides fragilis and Veillonella species 3 were consistently amongst the most abundant species at the earlier time points before 4 being outnumbered by Faecalibacterium prausnitzii and Prevotella copri at 12 and 18 5 6 months of age. Taxonomic α -diversity metrics and gene richness tended to decline or remain stable over the first 4-6 months of life, during exclusive breast-feeding, but 7 increased as expected with infant age from 6-18 months of age (Fig. S3a-b), with the 8 9 introduction of complementary feeds. A large proportion of variation in both compositional $(R^2 = 0.198, P < 0.001)$ and functional β -diversity ($R^2 = 0.378, P < 0.001$) was explained by 10 age (Fig. 1a-b and S3 c-d). 11

12

We employed extreme gradient boosting machines (XGBoost), a machine learning 13 14 approach, to train and test a model of compositional and functional microbiome maturation, with child age as an outcome. Children who were born to HIV-negative 15 mothers, who were non-stunted at 18 months (LAZ > -2) and had at least 2 stool samples 16 17 collected were used as a 'training set', which was then used to predict child age in the remaining samples (test set). Using species composition, the microbiome was highly 18 predictive of child age (Model pseudo- $R^2 = 0.77$, MAE = 1.4 months). This 'microbiota 19 20 age' score was also strongly correlated with biological age in the subset of children from the test set who were also non-stunted and born to HIV-negative mothers (pseudo- R^2 = 21 22 0.67). The species most strongly predictive of age included Faecalibacterium prausnitzii, 23 Blautia wexlerae, Prevotella copri, Staphylococcus hominis, Dorea formicigenerans,

Bifidobacterium longum, Agathobaculum butyriciproducens, Bifidobacterium bifidum, 1 Bacteroides thetaiotaomicron, Streptococcus vestibularis and Veillonella parvula (Fig. 2 1c). Metagenomic pathways also predicted age with high accuracy (Model pseudo- $R^2 =$ 3 0.68; MAE = 1.5; Fig. 1d). The pathways most strongly predictive of age included 4 methanogenesis from acetate (METH-ACETATE-PWY), multiple nucleotide and amino 5 6 acid metabolic pathways, including L-tryptophan biosynthesis (TRPSYN-PWY), purine ribonucleosides degradation (PWY0-1296), pyrimidine deoxyribonucleotides de novo 7 biosynthesis I (PWY-7184), L-histidine degradation I (HISDEG-PWY), dTDP-L-rhamnose 8 9 biosynthesis I (DTDPRHAMSYN-PWY), flavin biosynthesis I (RIBOSYN2-PWY) and nitrate reduction I (DENITRIFICATION-PWY). This 'metagenome age' was also highly 10 correlated with age in the subset of children from the test set who were also non-stunted 11 and born to HIV-negative mothers (pseudo- $R^2 = 0.67$). Using these models, we created 12 a microbiota-for-age Z-score (MAZ) and metagenome-for-age Z-score (MetAZ), which 13 accounted for variance of microbiota ages with respect to chronological ages at each 14 study visit (see Methods). The top 20 features contributing most strongly to age 15 predictions are plotted in Fig.1e-f. 16

17

18 WASH and IYCF interventions have little influence on the infant gut microbiome

We have previously reported in the SHINE trial that the WASH intervention had no impact on infant growth, whilst the IYCF intervention increased LAZ scores by 0.16, leading to a 23% reduction in stunting by 18 months of age. We tested whether these randomized interventions impacted any metrics of gut microbiome diversity or maturity in each age group. By performing principal coordinate analysis (PCoA) on Bray-Curtis distances of

taxonomic data and functional data we found no significant differences in β-diversity 1 between IYCF and non-IYCF arms at any time-point. There was a significant difference 2 in Bray-Curtis distances for microbiome composition between WASH and non-WASH 3 arms at the 3-month time-point (PERMANOVA, P=0.013; R²= 0.011), but at no other time-4 points (Fig.2a-d). No significant differences were observed in α -diversity metrics or gene 5 6 richness between WASH versus non-WASH arms nor IYCF versus non-IYCF arms at any time-point (Fig.2e-f). Using multivariable regression analyses (MaAsLin2), there were 7 also no differences in the relative abundance of species or pathways between intervention 8 9 arms apart from a small number of features at 3 months in the WASH arms (increased Collinsella aerofaciens and more abundant Klebsiella pneumoniae. reduced 10 metagenomic pathways involved in biotin and folate synthesis) and at 18 months in the 11 (reduced Eubacterium siraeum, E. rectale and Agathobaculum 12 IYCF arms *butyriciproducens*; Table S3 and S4). 13

14

15 *HIV exposure comprehensively alters infant gut microbiome composition and* 16 *function*

We previously reported in this cohort that maternal HIV exposure significantly impacts infant growth, whereby CHEU displayed significantly poorer linear growth compared with children who are HIV-unexposed (CHU) (30). We assessed diversity metrics and microbiome maturity in CHEU versus CHU and found that CHEU displayed significantly greater diversity (Shannon index; Wilcoxon rank-sum test P = 0.002; Fig. 3a) and species richness (P = 0.01; Fig. 3b) compared with CHU at 12 months of age, although the size of the two groups was imbalanced within this age category (n=91 CHEU, n=27 CHU).

medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Other metrics of α -diversity were significantly lower in CHEU at 2 months of age 1 (evenness P = 0.04, Simpson index P = 0.04). Metagenomic gene richness was also 2 elevated in CHEU at 1, 3, 6 and 12 months (Wilcoxon rank-sum test P = 0.002, P = 0.059, 3 P = 0.007, P < 0.001, respectively; Fig. 3c). Analysis of taxonomic β -diversity between 4 CHEU and CHU also revealed significant differences at 1, 3, 6, 12 and 18 months 5 6 suggesting that in utero HIV exposure was significantly associated with gut microbiome succession and development throughout the first 18 months of life (Fig. 3d-e). HIV 7 exposure also explained a significant proportion of the variation in metagenome pathway 8 9 β -diversity (PERMANOVA, P = 0.002, R2 = 0.033) at 1 month of age (Fig. 3h-i), but not at later ages. We next tested the association between HIV exposure and gut microbiome 10 maturity. We found that CHEU displayed greater microbiome age and MAZ, and hence 11 microbiota over-maturity, compared with CHU at 12 months of age (median 14.7 vs 9.2 12 months; β = 3.18, P < 0.001), which tended to be higher in CHEU at 1 months and at 6 13 months also (P = 0.074 and P = 0.059, respectively; Fig.3 f-g). However, at 18 months 14 CHEU displayed lower microbiome age (15.3 vs 16.4 months; β = -1.1, P = 0.045 15 respectively). Similarly, CHEU displayed significantly greater metagenome ages and 16 17 MetAZ scores compared with CHU at 1 month ($\beta = 1.1$, p = 0.039) and 12 months of age $(\beta = 2.2, P = 0.04; Fig. 3j-k)$, suggesting that HIV exposure drives both compositional and 18 19 functional microbiome over-maturity. The proportion of CHEU receiving prophylactic 20 cotrimoxazole ranged from 56-83% across the 3, 6, 12 and 18-month study visits.

21

We next explored which species were differentially abundant between CHEU and CHU by performing multivariable regression analyses, adjusting for age at stool sample

collection, exclusive breastfeeding status, delivery mode, and randomised trial arm. 1 Between 1-3 months of age, two Bifidobacteria species, B. longum and B. bifidum (Fig. 2 4a-b), in addition to Veillonella seminalis were significantly less abundant in CHEU versus 3 CHU (q < 0.1; Table S3). Conversely, *Flavonifractor plautii* was significantly more 4 abundant in CHEU at 3 months (g = 0.02). At 18 months, B. bifidum was again significantly 5 6 less abundant in CHEU (q = 0.04), whilst two other Bifidobacteria species were also weakly associated with CHEU, whereby *B. breve* was lower and *B. pseudocatenulatum* 7 higher (q < 0.25). Regression analyses of metagenomic pathways with CHEU status 8 9 generated similar outcomes. Following adjustment for covariates, significant associations for metagenomic pathways were only present at 1 and 3 months of age. At 1 month of 10 age, these included significant negative associations between CHEU and amino acid 11 synthetic pathways (superpathway of L-threonine biosynthesis, superpathway of L-12 isoleucine biosynthesis I and L-lysine biosynthesis I; Fig. 4c-e) and positive associations 13 with pathways involved in the degradation of sugar derivatives, including fructuronate, 14 glucoronate and galacturonate (PWY 7242 D-fructuronate degradation, PWY 6507 4-15 deoxy-L-threo-hex-4-enopyranuronate degradation, GALACTUROCAT PWY 16 D-17 galacturonate degradation I, GALACT GLUCUROCAT PWY superpathway of hexuronide and hexuronate degradation and GLUCUROCAT PWY superpathway of 18 19 beta D-glucuronide and D-glucuronate degradation; Fig. 4f-h, Table S4). A handful of 20 pathways involved in fatty acid oxidation and fermentation (fatty acid beta oxidation 21 peroxisome and succinate fermentation to butanoate) were also significantly positively 22 associated with CHEU at 3 months of age.

23

1 *Microbiome functionality, but not composition, predicts linear and ponderal* 2 growth.

We next examined the relationship between taxonomic and functional features of the gut 3 microbiome and attained growth (LAZ and WHZ) and growth velocity (WHZ and LAZ 4 velocity, increase in z-score increments per day between visits) from 1-18 months of age 5 6 using XGBoost models. Models were run separately for each of the six age groups, stratified by maternal HIV status and run in two combinations of predictive features: (i) 7 microbiome features alone (species or pathways); and (ii) microbiome features and 8 9 epidemiological variables, which included maternal anthropometry, baseline WASH and infant diet variables, amongst others (Table S5). In models combining microbiome 10 features with epidemiological features, birthweight, maternal height, maternal mid-upper 11 arm circumference, and household wealth were all important predictors of attained infant 12 LAZ and WHZ and growth velocity. Models including microbiome taxonomic features 13 (species) alone performed poorly for both attained and growth velocity at every age 14 category and regardless of HIV exposure status (Fig. 5a and 6a), with a majority of models 15 resulting in pseudo- R^2 values < 0. Model performance for linear growth improved when 16 17 epidemiological features were included, suggesting that gut microbiota composition alone was poorly predictive of growth. Taxonomic features were weakly predictive of WHZ 18 velocity at 1-3 months (pseudo-R² 0.09-0.12) and attained WHZ at 6 months (pseudo-R² 19 20 = 0.22), but only in children born to HIV-negative mothers (Fig. 6a). Conversely, models containing functional metagenomic pathways were moderately predictive of both attained 21 and future growth throughout 18 months of age (pseudo- R^2 = 0-0.55; Fig. 5a and 6a) 22 23 albeit with relatively large mean absolute errors (MAE) for both linear (0.48-0.95 LAZ) and

ponderal growth models (0.6-1.18 WHZ). The inclusion of epidemiological variables in the
metagenomic models added little to performance suggesting that pathway features were
independently predictive of both linear and ponderal growth. Models predicted WHZ
better than LAZ and models including children born to HIV-negative mothers also tended
to perform better. MAE decreased in all models as age increased (Fig. S4 a-d).

6

7 Microbiome features associated with linear growth

In all but the 2-month age group, birthweight contributed most strongly to prediction of 8 9 attained LAZ. Metagenomic pathways consistently performed better as predictors than other epidemiological features including maternal height. The most predictive pathways 10 were largely similar between infants born to HIV-positive and HIV-negative mothers. At 1 11 month and 2-months, metagenomic pathways encoding enzyme co-factor biosynthesis, 12 nucleotide degradation and biosynthesis and amino acid biosynthesis were consistently 13 14 predictive of both attained LAZ and LAZ velocity (Fig. 5b). Accumulated local effects (ALE) (36, 37) plots show the average effect of some of the most important features on 15 model outcomes (Fig. 6c). At 3 months and 6 months, pathways encoding fermentation 16 17 and carbohydrate biosynthesis were consistently predictive of attained LAZ and LAZ velocity, whilst amino acid degradation pathways, amongst others, were predictive of 18 19 growth at the oldest age groups. In particular, pathways involved in vitamin B biosynthesis 20 (flavin, folate, biotin, thiazole and cobalamin biosynthetic pathways) were consistently 21 predictive of attained LAZ, and included flavin biosynthesis I, 6-hydroxymethyldihydropterin diphosphate biosynthesis, superpathway of tetrahydrofolate biosynthesis, 22 23 adenosylcobalamin salvage from cobinamide I, biotin biosynthesis II and thiazole

medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

biosynthesis I. Increasing abundances of B vitamin biosynthesizing genes contributed to 1 increasing predicted growth in ALE plots, apart from Thiamin biosynthesis, which 2 predicted lower LAZ at 12 months (Fig. 5c). At 12 months of age, 4-coumarate 3 degradation (anaerobic), a pathway involved in plant polysaccharide degradation, was 4 the most predictive pathway of LAZ in children born to HIV-positive mothers, with greater 5 6 abundance associated with greater LAZ. We also assessed pathways predicting growth velocity and found similar results to that of attained growth (Fig. S5a). At 2 months of age, 7 folate biosynthetic pathways (folate transformations II and N10-formyl-tetrahydrofolate 8 9 biosynthesis) were the top two predictive features of linear growth velocity in children born to HIV-negative mothers, whilst at 3 months, purine and pyrimidine pathways were 10 amongst the most predictive features of linear growth velocity. Similarly, as per the 11 attained growth models, amino acid and fatty acid biosynthetic pathways were also 12 strongly predictive. Glycogen biosynthesis pathways were also consistently predictive of 13 14 linear growth velocity at all ages from 2 months onwards.

15

16 Microbiome features associated with ponderal growth

In the few models incorporating taxonomic features that weakly predicted WHZ velocity in infants born to HIV-negative mothers, *Escherichia coli* at 2 months and *Bacteroides fragilis* and *Veillonella atypica* at 3 months were amongst the most predictive features (Fig. S6). Many of the same categories of biosynthetic microbiota pathways were predictive of both WHZ and LAZ, including amino acid and nucleotide (especially purine biosynthesis) biosynthetic pathways in addition to a number of lipid synthesis pathways at older age groups (Fig. 6b-c). The most predictive pathways were largely similar

between infants born to HIV-positive and HIV-negative mothers. O-antigen biosynthesis 1 pathways (PWY-7328 UDP-glucose-derived O-antigen building blocks biosynthesis & 2 PWY-7332 UDP-N-acetylglucosamine-derived O-antigen building blocks biosynthesis 3 and OANTIGEN-PWY pathway), which did not appear in LAZ models, were consistently 4 amongst the most predictive features of WHZ at 1, 6, 12 and 18 months, whereby greater 5 6 abundance was associated with reduced growth. Pyrimidine and purine synthetic pathways were consistently the strongest predictors of WHZ velocity with varying 7 directions of association, including superpathway of pyrimidine deoxyribonucleotides de 8 9 novo biosynthesis (PWY0-166) which was the strongest predictive feature of WHZ velocity at 12 months in children born to HIV-mothers (Fig. S5b). Similar to the attained 10 WHZ models, O-antigen biosynthesis pathways, amino acid synthetic pathways and 11 glycogen biosynthesis pathways were all strongly predictive of ponderal growth velocity. 12

13

14

15 **DISCUSSION**

We report the succession and maturation of the early-life gut microbiome in a cohort of 16 17 335 children from rural Zimbabwe through the first 18 months after birth. We find that taxonomic composition of the gut microbiome is poorly predictive of child growth, however 18 19 functional composition moderately predicts both attained LAZ/WHZ and LAZ/WHZ 20 velocity, with pathways including B vitamin and nucleotide biosynthesis genes amongst 21 the most predictive of child growth. We also report that randomized WASH and IYCF 22 interventions have little impact on early-life gut microbiome composition, whilst maternal 23 HIV infection, which is associated with impaired infant growth, is associated with over-

maturity of the gut microbiome, featuring a depletion in commensal *Bifidobacteria*species. Collectively, these data suggest that disturbances in the functional potential of
the infant gut microbiome may contribute to poor infant growth and that interventions
targeting the infant gut microbiome may serve as novel solutions to combat child stunting,
particularly in CHEU.

6

Our previous data from the SHINE trial found that the WASH intervention had no impact 7 on linear growth, whilst IYCF improved growth by 0.16 LAZ (35). Furthermore, WASH had 8 9 no impact on carriage of enteropathogens or diarrheal incidence (14). Here, we show that the improved WASH and IYCF interventions also had little impact on the infant gut 10 microbiome throughout 18 months after birth. Our results support those from high-income 11 settings, showing a structured, programmed assembly of the gut microbiome in healthy 12 children who are born by vaginal delivery and exclusively breastfed (17, 38). These data 13 14 suggest that this programmed microbial maturation is robust to changes in WASH and complementary feeding, as delivered in this trial, and that potential microbiome-mediated 15 pathways affecting early-life growth occur independently of these specific interventions. 16 17 Improvements in growth as a result of the IYCF intervention are not driven by the microbiome, as supported by previous reports showing that the gut microbiome does not 18 19 mediate the effect of lipid-based IYCF nutrient supplements on child growth (39). More 20 intensive interventions that target WASH, microbial exposures, nutrient intake and 21 microbiota-directed foods during the first 2 years of life may be required to modify this 22 programmed trajectory of gut microbiome succession.

23

medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

The data reported here complement previous research associating the gut microbiome 1 with infant growth. The composition and maturity of the gut microbiota has been shown 2 to be disturbed during severe acute malnutrition (SAM) and could be used to predict 3 growth recovery (19). More recently, an "ecogroup" of 15 bacterial taxa has been 4 identified that exhibits consistent covariation, thereby representing microbiota maturation, 5 6 throughout the first 2 years after birth across different geographical cohorts (40). However, little research has examined microbiome maturation in the context of child 7 stunting. We report similar maturation of the early-life microbiome in this stunting cohort, 8 9 driven by many of the same age-predictive taxa as previously reported, notably Faecalibacterium prausnitzii as the species most predictive of age. We extend this to 10 report functional maturation of the early-life gut microbiota and find that, in addition to 11 amino acid and B-vitamin biosynthetic pathways, methanogenesis from acetate (METH-12 ACETATE-PWY) was the pathway most predictive of age, despite the apparent lack of 13 methanogens. The predictive strength of this pathway may reflect accumulation of 14 acetogenic species, including Blautia wexlerae, that feed into reactions upstream of the 15 METH-ACETATE-PWY. However, our results contrast with previous cross-sectional 16 17 studies reporting an association between the taxonomic composition of the gut microbiome and stunting (31-33). A previous study from sub-Saharan Africa (Afribiota) 18 19 reported significant differences in the fecal microbiome of stunted and non-stunted 20 children between 2-5 years of age, hypothesizing that decompartmentalization of the 21 gastrointestinal tract and overgrowth of oropharyngeal taxa are associated with stunting (31). We report here no association between the taxonomic composition of the gut 22 23 microbiome and linear growth, however our study examined children at younger ages to

that of the Afribiota cohort, suggesting that differences in the taxonomic composition of
the gut microbiome mediating linear growth may only manifest later in childhood.

3

We identified a range of metagenomic pathways that predicted linear and ponderal growth 4 through 18 months suggesting that the potential influence of an altered gut microbiome 5 6 on child growth is dependent upon a number of interacting metagenomic pathways. This discrepancy in the ability of functional metagenomic features versus taxonomic features 7 to predict growth may suggest that metagenomic pathways contributing to differences in 8 9 early-life growth may be harboured across a number of functionally redundant species. Intriguingly, many of the pathways that we found predictive of growth in infants, were also 10 found to be predictive of infant birthweight and neonatal growth in analysis of maternal 11 gut microbiomes from the same study cohort (27). Glycogen synthase was the pathway 12 most predictive of birthweight in maternal microbiomes, whereby higher abundance 13 14 predicted lower birthweight. Here we identified 2 related pathways (PWY-622 starch biosynthesis, GLYCOGENSYNTH-PWY glycogen biosynthesis I (from ADP-D-Glucose)) 15 that were consistently ranked as highly predictive of both linear and ponderal growth 16 17 velocity. Glycogen synthesis occurs as a starvation response in bacteria which facilitates transition into a biofilm state (41, 42). These data suggest that microbiome starvation 18 19 responses are associated with growth as early as the first months after birth, which may 20 have downstream implications for host metabolism and associated growth pathways. It is 21 plausible that these pathways are a result of altered nutrient composition in breastmilk of 22 mothers of stunted infants, thereby providing insufficient substrates for infant microbiome 23 maturation, as has been identified previously (43). Alternatively, these signatures may be

a consequence of a host-induced effect in poorly growing infants on gut microbiome
function.

3

Pathways encoding biosynthesis of B vitamins were consistently amongst the top 4 predictive features in models predicting both attained and LAZ and WHZ growth velocity. 5 6 Previous evidence supports the importance of B vitamins in early-life growth whereby maternal folic acid supplementation increases infant birthweight (44). In infants, vitamin 7 B12 status is predictive of both linear and ponderal growth (45), however the largest 8 9 randomized trial of B12 supplementation on infant growth to date showed no effect (46, 47). The gut microbiome biosynthesizes and metabolises B vitamins, including cobalamin 10 (B12) and folate (B9), at levels similar to dietary intake, and abundance of B vitamin-11 synthesizing genes in the infant gut microbiome differs by delivery mode, antibiotic 12 exposure (48), exclusive breastfeeding practices and geographic location, where vitamin 13 14 biosynthesis genes are greater in Western settings (38). Greater relative abundance of B vitamin biosynthetic pathways such as thiazole, tetrahydrofolate and flavin biosynthesis 15 in the maternal gut microbiome predicted greater birthweight and neonatal growth in this 16 17 same cohort, whilst biotin biosynthesis predicted reduced birthweight (27). The gut microbiome transferred from mother to infants may influence the metabolic capacity of 18 19 the infant microbiome to biosynthesize essential nutrients and influence downstream 20 growth pathways. Purine and pyrimidine biosynthetic pathways consistently contributed 21 to growth predictions across all age groups. In mothers from this same cohort, purine and 22 pyrimidine salvage pathways were associated with increasing birthweight (27). Meta-23 analyses have also found that dietary nucleotide supplementation in infants significantly

increases head circumference and rate of weight gain (49), suggesting that microbiomederived nucleotide metabolism may play an important role in nutritional status in early
infancy.

4

An important observation, however, is that many of these pathways predicting growth, 5 6 including B vitamin and purine/pyrimidine biosynthesis, were also predictive of age and hence microbiota maturation. There was a strong association between age and growth in 7 the SHINE cohort, whereby LAZ declined steadily between 1-18 months of age. This 8 9 highlights the difficulty in delineating the independent effect of the gut microbiome on growth during infancy, when the microbiome is concurrently undergoing age-related 10 maturation, which is by far the strongest contributor to gut microbiome variability. 11 Although we attempted to account for age-related effects by examining samples within 12 specified age categories, the microbiome-growth relationship observed here may be 13 14 confounded by age. Previous studies, employing MAZ as a maturation index to account for age have demonstrated microbiome maturation is disturbed in acutely malnourished 15 states (19) but is not associated with linear growth (50). Our observations that functional 16 17 microbiome characteristics moderately predict changes in linear growth add novel findings to this literature but need to be replicated in other large cohorts examining the 18 19 functional maturation of the gut microbiome throughout early childhood in similar settings.

20

We report that maternal HIV infection had a significant impact on the infant microbiome throughout the first 18 months after birth. We previously reported that CHEU have a 16% higher prevalence of stunting, 40% higher risk of infant mortality and poorer cognitive

medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

development compared with CHU (30). The results presented here raise the intriguing 1 possibility that altered succession and assembly of the infant gut microbiome may drive 2 some of these poorer clinical outcomes in CHEU. These findings are in line with previous 3 reports of disturbed gut microbiome composition in CHEU (25, 29). A number of factors 4 may explain these differences. Firstly, CHEU receive prophylactic cotrimoxazole from 6 5 6 weeks of age, which may impact gut microbiome succession throughout childhood (51, 52). However, we found the largest differences in gut microbiome composition and 7 function in samples from infants < 6 weeks of age, suggesting that these findings were 8 9 independent of antibiotic prophylaxis and that CHEU may acquire an altered microbiome from their mothers. We saw relatively minor differences, however, in the gut microbiome 10 of mothers living with HIV or without HIV in this same cohort (27). Although there were 11 significant differences in compositional beta diversity, the only species that differed in 12 abundance was Treponema berlinense, which was significantly less abundant in mothers 13 living with HIV. Exclusivity of breast-feeding is one of the most impactful factors 14 determining infant gut microbiome composition, however there was no significant 15 difference in EBF rates between CHEU and CHU in this cohort, suggesting that exclusivity 16 17 of breast-feeding was not responsible for these differences. Previous research has shown that the HMO content of breast milk differs between mothers living with and without HIV 18 19 (25). HMOs are the among the primary substrates for digestion by the infant gut 20 microbiome thereby fundamentally determining gut microbiome composition. Indeed, we 21 found that Bifidobacteria species, which are primary degraders of HMOs were 22 significantly less abundant in CHEU, as were genes involved in amino acid biosynthesis. 23 Previous, in-depth profiling of infant immune development has found that a lack of

Bifidobacteria in infancy is associated with systemic inflammation and immune dysregulation (21) which are also observed in CHEU (53-55), suggesting that the lack of commensal *Bifidobacteria* may mediate some of the poor immune, growth and clinical outcomes observed in CHEU.

5

6 This study is strengthened by the large birth cohort of healthy infants from two rural districts in sub-Saharan Africa. This population is underrepresented in microbiome 7 research to date. The use of whole metagenome shotgun sequencing strengthens the 8 9 study, providing a unique dataset in which to examine both compositional and functional microbiome maturation in early childhood. Furthermore, the machine learning approach 10 (XGBoost) and comprehensive clinical and epidemiologic data allows us to account for 11 environmental exposures influencing gut microbiome succession and infant growth in this 12 rural, low-resource settings. However, there are several limitations to this analysis: (i) the 13 14 SHINE microbiome sub-study included more HIV-positive mothers than the main SHINE trial (30% versus 15%), and the proportion of HIV-exposed infants varied by age group. 15 This resulted in some small sub-groups in some of our age categories by HIV exposure 16 17 analyses, which likely resulted in unstable predictions in certain XGBoost models; (ii) a significant proportion of the sequencing reads included in our datasets were not 18 19 annotatable (median 58.6%) using the specified bioinformatic pipelines (MetaPhIAn3 and 20 HUMAnN3). This large abundance of unknown sequences is common in samples derived 21 from non-Western populations (56) and leads to inferences solely being made from the assignable fraction, potentially missing important microbiota features that are predictive 22 23 of infant growth but are currently not represented in databases; (iii) Escherichia coli was

one of the most prevalent bacterial species across all age groups; however, MetaPhIAn3 1 cannot differentiate between E. coli pathotypes. Different E. coli pathotypes, such as 2 enteropathogenic and enteroaggregative E. coli have been associated with intestinal 3 pathology and EED, however we previously reported in the same cohort that some of 4 these pathotypes were not associated with growth (14); (iv) we attempted to account for 5 6 the age-related confounding of the microbiome-growth relationship by predicting attained growth and growth velocity in discrete age groups, but residual confounding may still be 7 present, influencing our ability to identify microbiome features independently associated 8 9 with growth; (v) data on infant antimicrobial use in the SHINE trial was incomplete, limiting 10 our ability to confidently assess this and other potential confounders; (vi) differences in microbiome composition and function may also be driven by differences in intestinal 11 microbial load, motility and biogeography, which were not assessed; (vii) finally, we chose 12 mother-infant pairs with the most complete sample collection during follow-up, in order to 13 14 strengthen our inferences about development of the gut microbiome over time. Baseline characteristics of the microbiome sub-cohort were largely similar to those of the larger 15 trial, suggesting that the microbiome sub-study cohort studied was largely representative 16 17 of the larger SHINE trial.

18

Collectively, these data suggest that HIV exposure shapes maturation of the infant gut microbiota, and that the functional composition of the infant gut microbiome is moderately predictive of infant growth in a population at high risk of stunting. Novel therapeutic approaches targeting the gut microbiome may mitigate the poor clinical outcomes that are observed in CHEU, a growing population of children in sub-Saharan Africa. By

contrast, current WASH and IYCF interventions fail to impact the infant gut microbiome
 and therefore transformative WASH and microbiome-targeted dietary interventions may
 prove to be more successful approaches to target the microbial pathways mediating early life growth.

- 5
- 6

7 MATERIALS AND METHODS

8 SHINE trial design

9 The study design and methods for The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial and for the corresponding microbiome analyses, have been reported 10 previously (57, 58). Briefly, SHINE was a 2x2 cluster-randomized trial, conducted 11 between 2012 and 2017, to determine the independent and combined effects of improved 12 infant and young child feeding (IYCF) and WASH on child stunting and anaemia in two 13 rural Zimbabwean districts (NCT01824940). 5280 pregnant women were cluster-14 randomized to one of four interventions: WASH, IYCF, WASH+IYCF, and Standard of 15 Care (SOC). The SOC interventions, included in all trial arms, comprised exclusive 16 17 breastfeeding promotion for all infants up to 6 months and strengthened prevention of mother to child transmission (PMTCT) of HIV services. The household WASH intervention 18 19 was initiated during pregnancy and was designed to reduce exposure to human and 20 animal feces, including, at the household level: construction of a ventilated improved pit 21 latrine, installation of two hand-washing stations plus monthly delivery of liquid soap and water chlorination solution, provision of a play space for the infant, and hygiene 22 23 counseling. The IYCF intervention was designed to improve infant diets using a small-

quantity lipid-based nutrient supplement (SQ-LNS), provided to the infant from 6-18
months, and educational interventions promoting the use of age-appropriate, locally
available foods and dietary diversity. Lastly, a combined trial arm, WASH+IYCF,
evaluated the effects of both improved WASH and infant nutrition.

5

6 Infants were followed up at study visits at 1, 3, 6, 12 and 18 months of age. Length and weight were measured at each infant visit, as described previously (35). Length-for-age 7 z scores (LAZ) and weight-for-height z scores (WHZ) were calculated from length and 8 9 weight measurements at each visit according to WHO Child Growth Standards. Epidemiologic data for the infants was collected from the baseline and follow-up visits 10 using trial questionnaires that included maternal anthropometry, birth outcomes, baseline 11 household WASH facilities, household wealth, maternal education, religion, parity, 12 household size, dietary diversity, changes in breastfeeding and complementary feeding 13 14 practices, food security, 7-day and 3-month infant health status, and antimicrobial use.

15

16 HIV testing

HIV testing was conducted on mothers at the baseline visit using a rapid test algorithm (Alere Determine HIV1/2 test, followed by INSTI HIV-1/2 test if positive). Those testing positive for HIV had CD4 counts measured (Alere Pima Analyser) and referral to local clinics; women were encouraged to begin co-trimoxazole prophylaxis and ART, to exclusively breastfeed, and to attend clinic at 6 weeks postpartum for early infant diagnosis and infant co-trimoxazole prophylaxis. Women testing negative for HIV were offered retesting at 32 gestational weeks and 18 months postpartum. Children of mothers

living with HIV were offered testing for HIV at each of the study visits. Those who tested 1 positive were referred to local clinics for ART. HIV was diagnosed using DNA PCR on 2 dried blood-spot samples or RNA PCR on plasma in samples collected prior to 18 months. 3 In samples collected after 18 months, HIV was diagnosed by PCR or rapid test algorithm, 4 depending on samples provided. Children born to HIV-positive mothers and whom tested 5 6 negative at 18 months were classified as HIV-exposed uninfected (CHEU). Inconclusive or discordant results were re-tested; if no further samples were available or repeat testing 7 was inconclusive, children were classified as HIV-unknown. 8

9

10 *Microbiome sub-study*

All CHEU and a subgroup of CHU from the SHINE study were enrolled into an 11 Environmental Enteric Dysfunction (EED) sub-study (n=1,656 mother-child pairs); these 12 infants underwent intensive biological specimen collection at 1, 3, 6, 12 and 18 months 13 14 of age (58). The EED sub-study was therefore enriched for mothers living with HIV, by design. Sample selection for inclusion into the current microbiome study was conducted 15 to enhance longitudinal profiling of the mother and infants gut microbiota. Of the mother-16 17 infant pairs within the EED sub-study, those with least one maternal fecal specimen (of 2) possible) and at least 2 infant fecal specimens (of 5 possible) were included in the gut 18 19 microbiome analyses. An additional 94 samples collected at the 1 and 3-month visits, that 20 did not meet these criteria, but had microbiome sequencing data available from a 21 separate study examining rotavirus vaccine immunogenicity in the SHINE trial (59), were also included in these analyses. Infant ages varied at each study visit due to the allowable 22 23 window around the visit date for the larger SHINE trial. Therefore, for this microbiome

study, each stool samples were re-categorized into 6 age groups corresponding to
important stages in infant microbiome development: "1 month" (0-6 weeks), "2 months"
(7 weeks – <3 months), "3 months" (3-6 months), "6 months" (6-9 months), "12 months"
(9-15 months), and "18 months" (15-20 months).

5

6 Sample collection

Study visits were conducted by trained study nurses in participants' homes. Sterile stool 7 collection tubes were provided to mothers, who collected stool samples from their infants 8 9 on the morning of each study visit. Samples were placed in cool boxes immediately upon collection by study nurses and transported by motorbike to field laboratories where they 10 were aliquoted and stored at -80°C within 6 hours of collection before subsequent 11 transport to the central laboratory in Harare for long-term storage at -80°C. An aliguot of 12 each stool sample was shipped on dry ice by courier to the British Columbia Centre for 13 14 Disease Control in Vancouver, Canada. A strict cold chain was maintained throughout transport, ensuring no freeze-thaw cycles occurred between sample collection and 15 processing. 16

17

18 Whole metagenome library preparation and sequencing

DNA was extracted from 100-200mg of stool samples using the Qiagen DNeasy PowerSoil Kit as per the manufacturer's instructions. DNA quantity was assessed by fluorometry (QuBit) and quality confirmed by spectrophotometry (SimpliNano). 1µg DNA was subsequently used as input for metagenomic sequencing library preparation using the Illumina TruSeq PCR-free library preparation protocol, using custom end-repair,

adenylation and ligation enzyme premixes (New England Biolabs). The concentration and 1 size of constructed libraries were assessed by qPCR and by TapeStation (Agilent). DNA-2 free negative controls and positive controls (ZymoBIOMICS) were included in all DNA 3 extraction and library preparation steps. Libraries were pooled in random batches of 48 4 samples including one negative control. A set of specimens were subject to replicate DNA 5 6 extraction, library preparation and, sequencing to estimate the magnitude of technical variability among samples. Whole metagenome sequencing was performed with 125-7 nucleotide paired-end reads using either the Illumina HiSeg 2500 or HiSegX platforms at 8 9 Canada's Michael Smith Genome Sciences Centre, Vancouver, Canada.

10

11 **Bioinformatics**

Sequenced reads were trimmed of adapters and filtered to remove low-quality, short 12 (<70% raw read length), and duplicate reads, as well as those of human, other animal or 13 14 plant origin, using KneadData with default settings. Species composition was determined by identifying clade-specific markers from reads using MetaPhIAn3 with default settings 15 (60). Relative abundance estimates were obtained from known assigned reads, and 16 17 unknown read proportions were estimated from total, assigned and unassigned, reads. Percent human DNA was estimated from *KneadData* output, using the proportion of 18 19 quality-filtered reads that align to the human genome. Given the smaller viral genome 20 sizes, sequencing depth, and limitations of MetaPhIAn3 for virus identification, we did not 21 include viruses in our current analyses. We applied a minimum threshold of >0.1% relative 22 abundance and $\geq 5\%$ prevalence for all detected species. Metabolic pathway composition 23 was determined using HUMAnN3 with default settings against the UniRef90 database

(60). Pathway abundance estimates were normalized using reads per kilobase per million
mapped reads (RPKM) and then re-normalized to relative abundance. We applied a
minimum relative abundance threshold of 3x10⁻⁷% and ≥5% prevalence for all
metagenomic pathways.

5

6 Statistical analysis

All data were analysed using R (v.4.0.5). Microbiome data were handled using the 7 phyloseq package. Alpha diversity metrics were calculated using the vegan package. 8 9 Beta-diversity was estimated using the Bray-Curtis dissimilarity index and analysed by permutation analysis of variance (PERMANOVA). Differential abundance analysis of 10 species or functional pathways was assessed using multiple regression analyses using 11 the MaAsLin2 package (61). Four covariates were chosen for adjustment in MaAsLin2 12 regression models and included age at stool sample collection, exclusive breastfeeding 13 14 status (recorded at 3 months old), delivery mode, and randomised trial arm. These covariates were chosen based on biological plausibility and previous evidence of their 15 influence on gut microbiome composition in large birth cohorts (17). Adjustment for 16 17 multiple comparisons was performed using the Benjamini-Hochberg false discovery rate (FDR). 18

19

The SHINE trial did not observe an interaction between the randomized WASH and IYCF interventions and growth; therefore, randomised trial arms were combined into WASH versus non-WASH arms and IYCF versus non-IYCF arms for specified analyses. We restricted the IYCF analysis to the 6, 12 and 18 month visits, corresponding to the period

during which supplemental infant feeding was introduced (from 6 months of age). All
children, regardless of HIV status or exposure status were included in the growth
analyses (875 total stool samples). 16 samples had missing ages and were excluded from
age prediction models. Stool samples collected from children classified as HIV-unknown
(24 samples) or HIV-positive (4 samples) at 18 months were excluded from direct
comparisons of CHEU vs CHU infants.

7

8 XGBoost models

9 Relationships between the infant microbiome and age or growth (attained LAZ/WHZ and WHZ/LAZ velocity) were evaluated using extreme gradient boosting machines (XGBoost). XGBoost builds an optimized predictive model by creating an ensemble from a series of weakly predictive models. XGBoost is also non-parametric, can capture nonlinear relationships, and can accommodate high-dimensional data (62). The XGBoost models were developed using microbiome relative abundances (species or pathways) and all epidemiologic variables.

16

XGBoost model selection was performed in 3 stages as previously described (27). In brief, *BayesianOptimization* function of the *rBayesianOptimization* package was used with 10-fold cross-validation to select model hyperparameters by minimizing the mean squared error (MSE). Models with the lowest MSE (in the 5th percentile) were retained, and from these models the variables that contributed to the top 95% of variable importance by proportion were retained. In stage two, all epidemiologic variables were included with the microbiome variables obtained in stage one, and *BayesianOptimization*

medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

was re-run as for stage one but using leave-one-out cross-validation. Microbiome 1 variables that contributed to the top 95% of variable importance by proportion were 2 retained. In stage three, all epidemiologic variables, microbiome features, and 3 hyperparameters selected in stage two were used to fit our final models, using leave-one-4 out cross-validation to minimize the MSE. This 3-stage hyperparameter tuning and model 5 6 building was performed for two feature sets, one comprising microbiome features and a second comprising microbiome plus epidemiologic features; this was done to assess 7 model performance and to examine the contribution of epidemiologic versus microbiome 8 9 features. Separate models were built for attained LAZ and WHZ and growth velocity outcomes (13). We assessed microbiota composition and functional pathways 10 separately. XGBoost models were fit using the H20.ai engine and h20 R package 11 interface with the XGBoost package. XGBoost model performance was evaluated using 12 pseudo- R^2 and mean absolute error (MAE). Pseudo- R^2 values < 0 indicated that the 13 14 prediction of the model was worse than the mean response. Scaled relative importance for each model feature was used to identify the twenty most informative variables for 15 further interpretation, where the most important variable is ranked first, and the 16 17 importance of subsequent variables are relative to the first variable. The marginal relationships between the twenty most important features and each growth outcome were 18 19 visualized for interpretation (36) using accumulated local effects plots (ALE). ALE plots 20 can be interpreted as showing a marginal effect, adjusted for all covariates retained in the 21 final model, showing the expected change in the outcome variable per increment in a 22 model feature. The resulting effect sizes are plotted cumulatively and centered about the 23 average effect size (37). ALEs were generated using the ALEplot package, modified to

compute confidence intervals, and were plotted using *ggplot2*. Standard deviations were
 calculated per increment and were used to calculate and plot increment-wise 95%
 confidence intervals.

4

5 Microbiome age

6 We investigated microbiome maturation by building an age prediction model using XGBoost and microbiome features only (species or pathways). We partitioned the infants 7 and their corresponding datasets into three groups to train and test a model of microbiome 8 age: (1) CHU with LAZ > -2 at 18 month of age, who contributed >1 dataset (healthy 9 training set), (2) remaining CHU infants with LAZ > -2 at 18 month of age, who contributed 10 a single metagenomic dataset (healthy test set); and (3) CHEU or children with LAZ \leq -2 11 at 18 months of age (unhealthy test set). Age was log transformed as a response in the 12 XGBoost model. We performed the same 3-stage tuning and model building procedure, 13 14 as described above. We generated model performance metrics, including pseudo-R2, mean absolute error (MAE) and mean squared error (MSE) for the three sets. For the 15 training set, we used the cross-validation, hold-out predictions to generate the metrics, 16 17 and for the two test sets, we used the predicted values from the final to calculate the model performance metrics. We exponentiated the predicted log transformed ages and 18 19 plotted these values against the observed age. The predicted age using these models is 20 referred to as 'microbiota age' for the models trained using species and 'metagenome 21 age' for models trained using pathways. To account for variance of microbiota ages with respect to chronological age within the age range of each study visit, a microbiota for age 22 23 Z-score (MAZ) and metagenome-for-age Z-score (MetAZ) was also created using the

1	microbiome age and metagenome ages as previously described (19). A Z-score was
2	calculated to account for variation in ages within each study visit using the following
3	formula:
4	
5	(Microbiota age of child – median microbiota age of 'healthy' child at same study visit)/
6	standard deviation of microbiota age of 'healthy' child at same study visit.
7	
8	
9	SUPPLEMENTARY MATERIALS:
10	
11	Fig. S1. Participants and samples included in the study.
12	
13	Fig. S2. Whole metagenome sequencing performance.
14	
15	Fig. S3. Diversity metrics in entire dataset.
16	
17	Fig. S4. XGBoost model performance metrics as assessed by mean absolute error.
18	
19	Fig. S5. Top ranked pathways in XGBoost models predicting growth velocity.
20	
21	Fig. S6. Figure S5. Top ranked species in XGBoost models predicting growth.
22	

1	Table S1. Baseline characteristics of infants in SHINE trial and microbiome sub-
2	study
3	
4	Table S2. Detected Eukaryota and Archaea species prior to prevalence filtering
5	
6	Table S3. Multivariate regression analysis examining the effect of maternal HIV
7	infection, age (days), exclusive breastfeeding status, delivery mode and trial arm
8	on taxonomic microbiome composition
9	
10	Table S4. Multivariate regression analysis examining the effect of maternal HIV
11	infection, age (days), exclusive breastfeeding status, delivery mode and trial arm
12	on gene pathway microbiome composition
13	
14	Table S5. Epidemiological variables included in XGBoost models
15	
16	
17	REFERENCES
18	1. Victora CG, Christian P, Vidaletti LP, Gatica-Domínguez G, Menon P, Black RE. Revisiting
19	maternal and child undernutrition in low-income and middle-income countries: variable progress
20	towards an unfinished agenda. Lancet. 2021;397(10282):1388-99.
21	2. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, Ezzati M, Grantham-
22	McGregor S, Katz J, Martorell R, Uauy R, Group MaCNS. Maternal and child undernutrition and
23	overweight in low-income and middle-income countries. Lancet. 2013;382(9890):427-51.

Prendergast AJ, Humphrey JH. The stunting syndrome in developing countries. Paediatr
 Int Child Health. 2014;34(4):250-65.

Dewey KG, Begum K. Long-term consequences of stunting in early life. Matern Child Nutr.
 2011;7 Suppl 3:5-18.

5 5. Dewey KG, Stewart CP, Wessells KR, Prado EL, Arnold CD. Small-quantity lipid-based 6 nutrient supplements for the prevention of child malnutrition and promotion of healthy 7 development: overview of individual participant data meta-analysis and programmatic 8 implications. Am J Clin Nutr. 2021;114(Suppl 1):3S-14S.

9 6. Prendergast A, Kelly P. Enteropathies in the developing world: neglected effects on global
 10 health. Am J Trop Med Hyg. 2012;86(5):756-63.

7. Harper KM, Mutasa M, Prendergast AJ, Humphrey J, Manges AR. Environmental enteric
 dysfunction pathways and child stunting: A systematic review. PLoS Negl Trop Dis.
 2018;12(1):e0006205.

Crane RJ, Jones KD, Berkley JA. Environmental enteric dysfunction: an overview. Food
 Nutr Bull. 2015;36(1 Suppl):S76-87.

Kosek MN, Investigators M-EN. Causal Pathways from Enteropathogens to
 Environmental Enteropathy: Findings from the MAL-ED Birth Cohort Study. EBioMedicine.
 2017;18:109-17.

Prendergast AJ, Kelly P. Interactions between intestinal pathogens, enteropathy and
 malnutrition in developing countries. Curr Opin Infect Dis. 2016;29(3):229-36.

Amadi B, Zyambo K, Chandwe K, Besa E, Mulenga C, Mwakamui S, Siyumbwa S, Croft
S, Banda R, Chipunza M, Chifunda K, Kazhila L, VanBuskirk K, Kelly P. Adaptation of the small
intestine to microbial enteropathogens in Zambian children with stunting. Nat Microbiol.
2021;6(4):445-54.

Pickering AJ, Null C, Winch PJ, Mangwadu G, Arnold BF, Prendergast AJ, Njenga SM,
Rahman M, Ntozini R, Benjamin-Chung J, Stewart CP, Huda TMN, Moulton LH, Colford JM, Luby
SP, Humphrey JH. The WASH Benefits and SHINE trials: interpretation of WASH intervention
effects on linear growth and diarrhoea. Lancet Glob Health. 2019;7(8):e1139-e46.
Mutasa K, Ntozini R, Mbuya MNN, Rukobo S, Govha M, Majo FD, Tavengwa N, Smith
 LE, Caulfield L, Swann JR, Stoltzfus RJ, Moulton LH, Humphrey JH, Gough EK, Prendergast AJ.
 Biomarkers of environmental enteric dysfunction are not consistently associated with linear
 growth velocity in rural Zimbabwean infants. Am J Clin Nutr. 2021;113(5):1185-98.

Rogawski McQuade ET, Platts-Mills JA, Gratz J, Zhang J, Moulton LH, Mutasa K, Majo
FD, Tavengwa N, Ntozini R, Prendergast AJ, Humphrey JH, Liu J, Houpt ER. Impact of Water
Quality, Sanitation, Handwashing, and Nutritional Interventions on Enteric Infections in Rural
Zimbabwe: The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) Trial. J Infect Dis.
2020;221(8):1379-86.

10 15. Rogawski ET, Liu J, Platts-Mills JA, Kabir F, Lertsethtakarn P, Siguas M, Khan SS, 11 Praharaj I, Murei A, Nshama R, Mujaga B, Havt A, Maciel IA, Operario DJ, Taniuchi M, Gratz J, Stroup SE, Roberts JH, Kalam A, Aziz F, Qureshi S, Islam MO, Sakpaisal P, Silapong S, Yori PP, 12 Rajendiran R, Benny B, McGrath M, Seidman JC, Lang D, Gottlieb M, Guerrant RL, Lima AAM, 13 14 Leite JP, Samie A, Bessong PO, Page N, Bodhidatta L, Mason C, Shrestha S, Kiwelu I, Mduma ER, Igbal NT, Bhutta ZA, Ahmed T, Hague R, Kang G, Kosek MN, Houpt ER, Investigators M-15 EN. Use of guantitative molecular diagnostic methods to investigate the effect of enteropathogen 16 infections on linear growth in children in low-resource settings: longitudinal analysis of results 17 18 from the MAL-ED cohort study. Lancet Glob Health. 2018;6(12):e1319-e28.

Richard SA, McCormick BJJ, Murray-Kolb LE, Lee GO, Seidman JC, Mahfuz M, Ahmed
 T, Guerrant RL, Petri WA, Rogawski ET, Houpt E, Kang G, Mduma E, Kosek MN, Lima AAM,
 Shrestha SK, Chandyo RK, Bhutta Z, Bessong P, Caulfield LE, Investigators M-EN. Enteric
 dysfunction and other factors associated with attained size at 5 years: MAL-ED birth cohort study
 findings. Am J Clin Nutr. 2019;110(1):131-8.

Stewart CJ, Ajami NJ, O'Brien JL, Hutchinson DS, Smith DP, Wong MC, Ross MC, Lloyd
 RE, Doddapaneni H, Metcalf GA, Muzny D, Gibbs RA, Vatanen T, Huttenhower C, Xavier RJ,
 Rewers M, Hagopian W, Toppari J, Ziegler AG, She JX, Akolkar B, Lernmark A, Hyoty H, Vehik
 K, Krischer JP, Petrosino JF. Temporal development of the gut microbiome in early childhood
 from the TEDDY study. Nature. 2018;562(7728):583-8.

18. Robertson RC, Manges AR, Finlay BB, Prendergast AJ. The Human Microbiome and
Child Growth - First 1000 Days and Beyond. Trends Microbiol. 2019;27(2):131-47.

Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, Benezra A,
 DeStefano J, Meier MF, Muegge BD, Barratt MJ, VanArendonk LG, Zhang Q, Province MA, Petri
 WA, Ahmed T, Gordon JI. Persistent gut microbiota immaturity in malnourished Bangladeshi
 children. Nature. 2014;510(7505):417-21.

Rouhani S, Griffin NW, Yori PP, Gehrig JL, Olortegui MP, Salas MS, Trigoso DR, Moulton
LH, Houpt ER, Barratt MJ, Kosek MN, Gordon JI. Diarrhea as a Potential Cause and
Consequence of Reduced Gut Microbial Diversity Among Undernourished Children in Peru. Clin
Infect Dis. 2020;71(4):989-99.

9 21. Blanton LV, Charbonneau MR, Salih T, Barratt MJ, Venkatesh S, Ilkaveya O,
10 Subramanian S, Manary MJ, Trehan I, Jorgensen JM, Fan YM, Henrissat B, Leyn SA, Rodionov
11 DA, Osterman AL, Maleta KM, Newgard CB, Ashorn P, Dewey KG, Gordon JI. Gut bacteria that
12 prevent growth impairments transmitted by microbiota from malnourished children. Science.
13 2016;351(6275).

Smith MI, Yatsunenko T, Manary MJ, Trehan I, Mkakosya R, Cheng J, Kau AL, Rich SS,
Concannon P, Mychaleckyj JC, Liu J, Houpt E, Li JV, Holmes E, Nicholson J, Knights D, Ursell
LK, Knight R, Gordon JI. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor.
Science. 2013;339(6119):548-54.

Chen RY, Mostafa I, Hibberd MC, Das S, Mahfuz M, Naila NN, Islam MM, Huq S, Alam
 MA, Zaman MU, Raman AS, Webber D, Zhou C, Sundaresan V, Ahsan K, Meier MF, Barratt MJ,
 Ahmed T, Gordon JI. A Microbiota-Directed Food Intervention for Undernourished Children. N
 Engl J Med. 2021;384(16):1517-28.

22 24. Gehrig JL, Venkatesh S, Chang HW, Hibberd MC, Kung VL, Cheng J, Chen RY,
23 Subramanian S, Cowardin CA, Meier MF, O'Donnell D, Talcott M, Spears LD, Semenkovich CF,
24 Henrissat B, Giannone RJ, Hettich RL, Ilkayeva O, Muehlbauer M, Newgard CB, Sawyer C, Head
25 RD, Rodionov DA, Arzamasov AA, Leyn SA, Osterman AL, Hossain MI, Islam M, Choudhury N,
26 Sarker SA, Huq S, Mahmud I, Mostafa I, Mahfuz M, Barratt MJ, Ahmed T, Gordon JI. Effects of
27 microbiota-directed foods in gnotobiotic animals and undernourished children. Science.
2019;365(6449).

Bender JM, Li F, Martelly S, Byrt E, Rouzier V, Leo M, Tobin N, Pannaraj PS, Adisetiyo
 H, Rollie A, Santiskulvong C, Wang S, Autran C, Bode L, Fitzgerald D, Kuhn L, Aldrovandi GM.
 Maternal HIV infection influences the microbiome of HIV-uninfected infants. Sci Transl Med.
 2016;8(349):349ra100.

5 26. Lozupone CA, Li M, Campbell TB, Flores SC, Linderman D, Gebert MJ, Knight R, Fontenot
6 AP, Palmer BE. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host
7 Microbe. 2013;14(3):329-39.

8 27. Gough EK, Edens TJ, Geum HM, Baharmand I, Gill SK, Robertson RC, Mutasa K, Ntozini
9 R, Smith LE, Chasekwa B, Majo FD, Tavengwa NV, Mutasa B, Francis F, Carr L, Tome J,
10 Stoltzfus RJ, Moulton LH, Prendergast AJ, Humphrey JH, Manges AR, Team ST. Maternal fecal
11 microbiome predicts gestational age, birth weight and neonatal growth in rural Zimbabwe.
12 EBioMedicine. 2021;68:103421.

Amenyogbe N, Dimitriu P, Cho P, Ruck C, Fortuno ES, Cai B, Alimenti A, Côté HCF, Maan
EJ, Slogrove AL, Esser M, Marchant A, Goetghebuer T, Shannon CP, Tebbutt SJ, Kollmann TR,
Mohn WW, Smolen KK. Innate Immune Responses and Gut Microbiomes Distinguish HIVExposed from HIV-Unexposed Children in a Population-Specific Manner. J Immunol.
2020;205(10):2618-28.

Machiavelli A, Duarte RTD, Pires MMS, Zárate-Bladés CR, Pinto AR. The impact of *in utero* HIV exposure on gut microbiota, inflammation, and microbial translocation. Gut Microbes.
 2019;10(5):599-614.

Stoltzfus RJ, Moulton LH, Humphrey JH, Prendergast AJ, Team SHINEST.
 Mortality, Human Immunodeficiency Virus (HIV) Transmission, and Growth in Children Exposed
 to HIV in Rural Zimbabwe. Clin Infect Dis. 2021;72(4):586-94.

31. Vonaesch P, Morien E, Andrianonimiadana L, Sanke H, Mbecko JR, Huus KE,
Naharimanananirina T, Gondje BP, Nigatoloum SN, Vondo SS, Kaleb Kandou JE,
Randremanana R, Rakotondrainipiana M, Mazel F, Djorie SG, Gody JC, Finlay BB, Rubbo PA,
Wegener Parfrey L, Collard JM, Sansonetti PJ, Investigators A. Stunted childhood growth is

associated with decompartmentalization of the gastrointestinal tract and overgrowth of
 oropharyngeal taxa. Proc Natl Acad Sci U S A. 2018;115(36):E8489-E98.

3 32. Dinh DM, Ramadass B, Kattula D, Sarkar R, Braunstein P, Tai A, Wanke CA, Hassoun S,
4 Kane AV, Naumova EN, Kang G, Ward HD. Longitudinal Analysis of the Intestinal Microbiota in
5 Persistently Stunted Young Children in South India. PLoS One. 2016;11(5):e0155405.

Gough EK, Stephens DA, Moodie EE, Prendergast AJ, Stoltzfus RJ, Humphrey JH,
Manges AR. Linear growth faltering in infants is associated with Acidaminococcus sp. and
community-level changes in the gut microbiota. Microbiome. 2015;3:24.

9 34. Ordiz MI, Stephenson K, Agapova S, Wylie KM, Maleta K, Martin J, Trehan I, Tarr PI,
10 Manary MJ. Environmental Enteric Dysfunction and the Fecal Microbiota in Malawian Children.
11 Am J Trop Med Hyg. 2017;96(2):473-6.

Humphrey JH, Mbuya MNN, Ntozini R, Moulton LH, Stoltzfus RJ, Tavengwa NV, Mutasa
K, Majo F, Mutasa B, Mangwadu G, Chasokela CM, Chigumira A, Chasekwa B, Smith LE, Tielsch
JM, Jones AD, Manges AR, Maluccio JA, Prendergast AJ, Team SHINEST. Independent and
combined effects of improved water, sanitation, and hygiene, and improved complementary
feeding, on child stunting and anaemia in rural Zimbabwe: a cluster-randomised trial. Lancet Glob
Health. 2019;7(1):e132-e47.

18 36. Zhao Q, Hastie T. Causal interpretations of black-box models. J Bus Econ Stat.19 2019;2019.

37. Apley D, Zhu J. Visualizing the effects of predictor variables in black box supervised
learning models. J R Stat Soc Ser B (Statistical Methodol). 2020;82:1059-86.

38. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris
M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, Reeder J, Kuczynski J,
Caporaso JG, Lozupone CA, Lauber C, Clemente JC, Knights D, Knight R, Gordon JI. Human
gut microbiome viewed across age and geography. Nature. 2012;486(7402):222-7.

39. Hughes RL, Arnold CD, Young RR, Ashorn P, Maleta K, Fan YM, Ashorn U, Chaima D,
Malamba-Banda C, Kable ME, Dewey KG. Infant gut microbiota characteristics generally do not

modify effects of lipid-based nutrient supplementation on growth or inflammation: secondary
analysis of a randomized controlled trial in Malawi. Sci Rep. 2020;10(1):14861.

40. Raman AS, Gehrig JL, Venkatesh S, Chang HW, Hibberd MC, Subramanian S, Kang G,
Bessong PO, Lima AAM, Kosek MN, Petri WA, Rodionov DA, Arzamasov AA, Leyn SA, Osterman
AL, Huq S, Mostafa I, Islam M, Mahfuz M, Haque R, Ahmed T, Barratt MJ, Gordon JI. A sparse
covarying unit that describes healthy and impaired human gut microbiota development. Science.
2019;365(6449).

8 41. Wilson WA, Roach PJ, Montero M, Baroja-Fernández E, Muñoz FJ, Eydallin G, Viale AM,
9 Pozueta-Romero J. Regulation of glycogen metabolism in yeast and bacteria. FEMS Microbiol
10 Rev. 2010;34(6):952-85.

42. Sekar K, Linker SM, Nguyen J, Grünhagen A, Stocker R, Sauer U. Bacterial Glycogen
 Provides Short-Term Benefits in Changing Environments. Appl Environ Microbiol. 2020;86(9).

43. Charbonneau MR, O'Donnell D, Blanton LV, Totten SM, Davis JC, Barratt MJ, Cheng J,
Guruge J, Talcott M, Bain JR, Muehlbauer MJ, Ilkayeva O, Wu C, Struckmeyer T, Barile D,
Mangani C, Jorgensen J, Fan YM, Maleta K, Dewey KG, Ashorn P, Newgard CB, Lebrilla C, Mills
DA, Gordon JI. Sialylated Milk Oligosaccharides Promote Microbiota-Dependent Growth in
Models of Infant Undernutrition. Cell. 2016;164(5):859-71.

44. Jonker H, Capelle N, Lanes A, Wen SW, Walker M, Corsi DJ. Maternal folic acid
supplementation and infant birthweight in low- and middle-income countries: A systematic review.
Matern Child Nutr. 2020;16(1):e12895.

45. Strand TA, Ulak M, Kvestad I, Henjum S, Ulvik A, Shrestha M, Thorne-Lyman AL, Ueland
PM, Shrestha PS, Chandyo RK. Maternal and infant vitamin B12 status during infancy predict
linear growth at 5 years. Pediatr Res. 2018;84(5):611-8.

46. Strand TA, Taneja S, Kumar T, Manger MS, Refsum H, Yajnik CS, Bhandari N. Vitamin
B-12, folic acid, and growth in 6- to 30-month-old children: a randomized controlled trial.
Pediatrics. 2015;135(4):e918-26.

47. Strand TA, Ulak M, Hysing M, Ranjitkar S, Kvestad I, Shrestha M, Ueland PM, McCann
A, Shrestha PS, Shrestha LS, Chandyo RK. Effects of vitamin B12 supplementation on

neurodevelopment and growth in Nepalese Infants: A randomized controlled trial. PLoS Med.
 2020;17(12):e1003430.

48. Vänni P, Tejesvi MV, Ainonen S, Renko M, Korpela K, Salo J, Paalanne N, Tapiainen T.
Delivery mode and perinatal antibiotics influence the predicted metabolic pathways of the gut
microbiome. Sci Rep. 2021;11(1):17483.

49. Wang L, Mu S, Xu X, Shi Z, Shen L. Effects of dietary nucleotide supplementation on
growth in infants: a meta-analysis of randomized controlled trials. Eur J Nutr. 2019;58(3):121321.

So. Kamng'ona AW, Young R, Arnold CD, Kortekangas E, Patson N, Jorgensen JM, Prado
EL, Chaima D, Malamba C, Ashorn U, Fan YM, Cheung YB, Ashorn P, Maleta K, Dewey KG. The
association of gut microbiota characteristics in Malawian infants with growth and inflammation.
Sci Rep. 2019;9(1):12893.

51. Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, Baumard L,
Choudhry N, Karmali Y, Bwakura-Dangarembizi M, Musiime V, Lutaakome J, Kekitiinwa A,
Mutasa K, Szubert AJ, Spyer MJ, Deayton JR, Glass M, Geum HM, Pardieu C, Gibb DM, Klein
N, Edens TJ, Walker AS, Manges AR, Prendergast AJ. Cotrimoxazole reduces systemic
inflammation in HIV infection by altering the gut microbiome and immune activation. Sci Transl
Med. 2019;11(486).

D'Souza AW, Moodley-Govender E, Berla B, Kelkar T, Wang B, Sun X, Daniels B,
 Coutsoudis A, Trehan I, Dantas G. Cotrimoxazole Prophylaxis Increases Resistance Gene
 Prevalence and α-Diversity but Decreases β-Diversity in the Gut Microbiome of Human
 Immunodeficiency Virus-Exposed, Uninfected Infants. Clin Infect Dis. 2020;71(11):2858-68.

53. Prendergast AJ, Chasekwa B, Rukobo S, Govha M, Mutasa K, Ntozini R, Humphrey JH.
Intestinal Damage and Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV)Exposed and HIV-Infected Zimbabwean Infants. J Infect Dis. 2017;216(6):651-61.

54. Jalbert E, Williamson KM, Kroehl ME, Johnson MJ, Cutland C, Madhi SA, Nunes MC,
Weinberg A. HIV-Exposed Uninfected Infants Have Increased Regulatory T Cells That Correlate
With Decreased T Cell Function. Front Immunol. 2019;10:595.

55. Dirajlal-Fargo S, Mussi-Pinhata MM, Weinberg A, Yu Q, Cohen R, Harris DR, Bowman E,
 Gabriel J, Kulkarni M, Funderburg N, Chakhtoura N, McComsey GA. HIV-exposed-uninfected
 infants have increased inflammation and monocyte activation. AIDS. 2019;33(5):845-53.

Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F, Beghini F, Manghi P, Tett
A, Ghensi P, Collado MC, Rice BL, DuLong C, Morgan XC, Golden CD, Quince C, Huttenhower
C, Segata N. Extensive Unexplored Human Microbiome Diversity Revealed by Over 150,000
Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. Cell. 2019;176(3):64962.e20.

9 57. Gough EK, Prendergast AJ, Mutasa KE, Stoltzfus RJ, Manges AR, Team SHINEST.
10 Assessing the Intestinal Microbiota in the SHINE Trial. Clin Infect Dis. 2015;61 Suppl 7:S738-44.

58. Humphrey JH, Jones AD, Manges A, Mangwadu G, Maluccio JA, Mbuya MN, Moulton LH,
Ntozini R, Prendergast AJ, Stoltzfus RJ, Tielsch JM, Team SHINEST. The Sanitation Hygiene
Infant Nutrition Efficacy (SHINE) Trial: Rationale, Design, and Methods. Clin Infect Dis. 2015;61
Suppl 7:S685-702.

15 59. Robertson RC, Church JA, Edens TJ, Mutasa K, Min Geum H, Baharmand I, Gill SK,
16 Ntozini R, Chasekwa B, Carr L, Majo FD, Kirkpatrick BD, Lee B, Moulton LH, Humphrey JH,
17 Prendergast AJ, Manges AR, Team ST. The fecal microbiome and rotavirus vaccine
18 immunogenicity in rural Zimbabwean infants. Vaccine. 2021;39(38):5391-400.

Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan A,
 Manghi P, Scholz M, Thomas AM, Valles-Colomer M, Weingart G, Zhang Y, Zolfo M, Huttenhower
 C, Franzosa EA, Segata N. Integrating taxonomic, functional, and strain-level profiling of diverse
 microbial communities with bioBakery 3. Elife. 2021;10.

Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, Tickle TL, Weingart G,
Ren B, Schwager EH, Chatterjee S, Thompson KN, Wilkinson JE, Subramanian A, Lu Y, Waldron
L, Paulson JN, Franzosa EA, Bravo HC, Huttenhower C. Multivariable association discovery in
population-scale meta-omics studies. PLoS Comput Biol. 2021;17(11):e1009442.

Chen T, Guestrin C, editors. XGBoost: A Scalable Tree Boosting System. *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*;
2016; New York, NY, USA: ACM.

Acknowledgements: We thank all the mothers, babies, and their families who 1 participated in the SHINE trial, the leadership and staff of the Ministry of Health and Child 2 Care in Chirumanzu and Shurugwi districts and Midlands Province (especially 3 environmental health, nursing, and nutrition) for their roles in operationalization of the 4 study procedures, the Ministry of Local Government officials in each district who 5 6 supported and facilitated field operations, Phillipa Rambanepasi and her team for proficient management of all the finances, Virginia Sauramba for management of 7 compliance issues, and the programme officers at the Gates Foundation and the 8 9 Department for International Development, who enthusiastically worked with us over a long period to make SHINE happen. 10

11

12 Funding:

- Bill & Melinda Gates Foundation (OPP1021542 and OPP1143707; JHH and AJP),
- 14 with a subcontract to the University of British Columbia (20R25498; ARM)
- Inited Kingdom Department for International Development (DFID/UKAID; JHH
 and AJP)
- 17 Wellcome Trust (093768/Z/10/Z, 108065/Z/15/Z; AJP)
- Swiss Agency for Development and Cooperation (JHH and AJP)
- US National Institutes of Health (2R01HD060338-06; JHH)
- 20 UNICEF (PCA-2017-0002; JHH and AJP).

The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

23

1 Author contributions:

- 2 Conceptualized and study design: ARM, LES, RJS, JHH and AJP.
- 3 Data and biospecimen collection: KM, RN, BC, FDM, NVT, JT, and BM
- 4 Biospecimen processing: HMG, IB, SKG, RCR, FF and LC
- 5 Bioinformatics and machine learning analyses: TJE
- 6 Data analysis and interpretation: RCR, ARM, TJE, LC, CE and EKG
- 7 Writing original draft: RCR, ARM, LC and TJE
- 8 Writing reviewing and editing: All authors
- 9 Supervision and verification of data: ARM, AJP and JHH

10

Competing interests: TJE was paid a scientific consulting fee in relation to the analysis
 of the data presented here by Zvitambo Institute for Maternal and Child Health Research.
 RCR declares remittance from Abbott Nutrition Health Institute (March 2022) and Nutricia
 (May 2021) for public conference talks outside the submitted work. All other authors
 declare that they have no competing interests.

16

Data and materials availability: Raw sequencing reads are deposited in the European Bioinformatics Database under accession number PRJEB51728. Associated metadata from the larger SHINE trial will be uploaded to http://ClinEpiDB.org following publication of all primary manuscripts from the SHINE trial. Prior to that time, the data are housed on the ClinEpiDB platform at the Zvitambo Institute for Maternal and Child Health Research and available upon request from Ms. Virginia Sauramba (vsauramba@zvitambo.co.zw).

23

Ethics approvals: All SHINE mothers provided written informed consent. The Medical Research Council of Zimbabwe (MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University of British Columbia (H15-03074) approved the study protocol, including the microbiome analyses. The SHINE trial is registered at ClinicalTrials.gov (NCT01824940).



Age (months)

1 Fig. 1. Compositional and functional maturation of the gut microbiome of 335

2 **infants from rural Zimbabwe from 1-18 months of age.** PCoA of Bray-Curtis distances

3 of species (a) and metagenomic pathways (b) coloured by age category. PERMANOVA

4 model results are also plotted. The top 20 features and model pseudo-R² from XGBoost

- 5 models predicting age using species (c) or pathways (d) are ranked by scaled feature
- 6 importance and relative abundance (0-1) plotted by age (e-f) to visualize taxonomic and
- 7 functional microbiome succession from 1-18 months of age.



Fig. 2. Impact of randomized WASH and IYCF interventions on infant gut 1 2 microbiome. PCoA of Bray-Curtis distances species coloured by WASH vs non-WASH arms (a), including PERMANOVA model results, and IYCF vs non-IYCF arms (b) are 3 plotted in addition to the first component (PC1) from PCoA of species (c) and pathways 4 (d). The IYCF intervention was introduced after 6 months of age, therefore direct 5 comparisons of IYCF vs non-IYCF arms are not shown in the 1-, 2- and 3-month age 6 categories. No significant differences were observed in Shannon alpha diversity (e) and 7 8 gene richness (f) according to trial arm.



1 Fig. 3. Maternal HIV infection comprehensively alters infant gut microbiome

2 diversity and maturity. Shannon alpha diversity (a), species richness (b) and gene

3 richness (c) shows significant over-diversification in CHEU vs CHU (Wilcoxon rank-sum

4 test; *p<0.05). PCoA of Bray-Curtis distances (d) and PC1 (e) of species composition in

- 5 CHEU vs CHU show significant differences throughout 18 months of life (PERMANOVA).
- 6 Microbiome age (f) and microbiome-for-age Z score (MAZ; g) shows significant
- 7 differences in gut microbiome maturity in CHEU vs CHU (linear regression analyses).
- 8 PCoA of microbiome gene pathways shows differences in CHEU vs CHU at 1 month of
- 9 age (h-i) in addition to differences in metagenomic maturity (j-k).



1	Fig. 4. Maternal HIV infection is associated with reduced abundance of
2	Bifidobacteria abundance and amino acid biosynthesis genes. Relative abundance
3	(0-1) of Bifidobacterium longum (a) and B. bifidum (b) in the gut microbiome of CHEU and
4	CHU at each age category via multivariate regression analyses. Multivariate regression
5	of gene pathways demonstrates reduced abundance of amino acid biosynthetic pathways
6	(c-e) and increase in abundance of pathways involved in degradation of sugar derivatives
7	(f-h). Multivariate regression using MaAsLin2 using default q < 0.25 cut-off. *q<0.1.



Fig. 5. Prediction of attained LAZ and LAZ velocity using XGBoost models. 1 Performance of XGBoost models as assessed by pseudo-R² values for prediction of 2 attained LAZ and LAZ velocity (LAZ increase per day to next study visit) using species or 3 metagenomic pathways, stratified by age category and maternal HIV status (a). Models 4 were run using microbiome features alone (species or metagenomic pathways; blue 5 6 points) and in combination with epidemiological variables (yellow points). The top ranked pathways predicting LAZ at each age category are plotted (b), stratified by maternal HIV 7 status and coloured by scaled importance in the XGBoost model. Accumulated effect 8 9 plots (ALE) of representative pathways ranking highly in XGBoost model predictions display change in predicted linear growth (LAZ or LAZ velocity) by percentile of the feature 10 abundance distribution. Tick marks on the x-axis are a rug plot of individual feature 11 abundance percentiles. ALEs were generated using the ALEplot package and were 12 plotted using gaplot2. Standard deviations (sd) were calculated per increment in 13 14 microbiome feature and were used to calculate and plot increment-wise 95% confidence intervals as the average change in the outcome ±1.96(sd/sqrt(n)), where n is the number 15 of observed feature values, and sd is the standard deviation of the change in the outcome 16 17 variable in an interval.



Fig. 6. Prediction of attained LAZ and LAZ velocity using XGBoost models. 1 Performance of XGBoost models as assessed by pseudo-R² values for prediction of 2 attained WHZ and WHZ velocity (WHZ increase per day to next study visit) using species 3 or metagenomic pathways, stratified by age category and maternal HIV status (a). Models 4 were run using microbiome features alone (species or metagenomic pathways; blue 5 6 points) and in combination with epidemiological variables (yellow points). The top ranked pathways predicting WHZ at each age category are plotted (b), stratified by maternal HIV 7 status and coloured by scaled importance in the XGBoost model. Accumulated effect 8 9 plots (ALE) of representative pathways ranking highly in XGBoost model predictions display change in predicted linear growth (LAZ or LAZ velocity) by percentile of the feature 10 abundance distribution. Tick marks on the x-axis are a rug plot of individual feature 11 abundance percentiles. ALEs were generated using the ALEplot package and were 12 plotted using *ggplot2*. Standard deviations (sd) were calculated per increment in 13 14 microbiome feature and were used to calculate and plot increment-wise 95% confidence intervals as the average change in the outcome ±1.96(sd/sqrt(n)), where n is the number 15 of observed feature values, and sd is the standard deviation of the change in the outcome 16 17 variable in an interval.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. Table S1. Baseline characteristics of infants in SHINE trial and microbiome substudy

	SHINE	Microbiome substudy
	N=4727	N=335
Mothers HIV+	738 (15.6%)	99 (29.6%)
Female	2329 (49.5%)	147 (43.9%)
Birthweight, kg (sd)	3.07 (0.5)	3.09 (0.49)
Low birthweight	410 (9.7%)	27 (8.2%)
Gestational age, weeks (sd)	38.4 (4.03)	39.2 (3.43)
Standard vaginal delivery	4000 (92.5%)	308 (93.9%)
Institutional delivery	3752 (88.2%)	294 (89.9%)
Exclusive breastfeeding	2397 (87.9%)	292 (91.0%)
LAZ - 1 month, (sd)	-0.9 (1.35)	-0.96 (1.25)
LAZ - 3 months, (sd)	-0.91 (1.33)	-0.94 (1.18)
LAZ - 6 months, (sd)	-0.95 (1.25)	-0.91 (1.15)
LAZ - 12 months, (sd)	-1.28 (1.22)	-1.21 (1.05)
LAZ - 18 months, (sd)	-1.58 (1.13)	-1.48 (1.07)
Trial arm		
SOC	1126 (23.8%)	88 (26.3%)
IYCF	1121 (23.7%)	93 (27.8%)
WASH	1201 (25.4%)	71 (21.2%)
WASH+IYCF	1279 (27.1%)	83 (24.8%)
Household size, [IQR]	5.00 [3.00;6.00]	5.00 [4.00;6.00]
Mother age, years (sd)	26.2 (6.66)	28.3 (6.35)
Mother height, cm (sd)	160.1 (5.94)	161 (5.78)
Parity, [IQR]	2.00 [1.00;3.00]	2.00 [1.00;3.00]
Maternal MUAC, cm (sd)	26.4 (3.08)	27.1 (3.23)
Maternal education, years (sd)	9.52 (1.85)	9.39 (1.90)
Mothers employed	383 (8.7%)	30 (9.17%)
Open defacation in household	1952 (44.8%)	154 (47.1%)
Any latrine in household	1743 (39.8%)	128 (40.3%)
Improved latrine in household	1535 (35.1%)	119 (37.4%)
Improved floor in household	2370 (54.2%)	183 (56.5%)
Household owns chickens	3512 (79.0%)	264 (80.5%)
Livestock in household	1691 (36.6%)	146 (44.0%)

medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. Table S2. Detected Eukaryota and Archaea species prior to prevalence filtering

Eukaryota	Archaea
Blastocystis sp subtype 1	Methanobrevibacter oralis
Candida albicans	Methanobrevibacter smithii
Cryptosporidium hominis	Methanobrevibacter woesei
Cryptosporidium meleagridis	Methanosphaera stadtmanae
Cryptosporidium parvum	
Giardia intestinalis	
Saccharomyces cerevisiae	

 Table S3. (Auxiliary supplementary file)
 Multivariate regression analysis

examining the effect of maternal HIV infection, age (days), exclusive breastfeeding

status, delivery mode and trial arm on taxonomic microbiome composition

Table S4. (Auxiliary supplementary file) Multivariate regression analysis examining

the effect of maternal HIV infection, age (days), exclusive breastfeeding status,

delivery mode and trial arm on gene pathway microbiome composition

Table S5. (Auxiliary supplementary file) Epidemiological variables included in

XGBoost models





collected from 335 unique infants underwent whole metagenome shotgun

sequencing and were categorized into 6 age groups (a). CONSORT diagram of the

participants from the SHINE trial included in the infant microbiome sub-study (b).







Sample

medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Figure S2. Whole metagenome sequencing performance. A median of 0.05% sequencing reads were assigned to the human genome in each sample (a), which varied by age at stool sample collection. The percentage of sequencing reads that could be aligned to known sequences using the MetaPhIAn3 and HUMAnN3 pipelines decreased in stool samples collected at older ages (b). PCoA (c) and phylum relative abundances (d) of sequencing sample replicates showed high reproducibility and little technical variation.





medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. **Figure S3. Diversity metrics in entire dataset**. Shannon alpha diversity (a) and gene richness (b) across the entire dataset revealed stable diversity up to 4-5 months of age followed by rapid taxonomic and functional diversification. Bray-curtis distances between samples at within and across each age visit showed low interindividual variability in species composition which increase with age (c), and high inter-individual variation in metagenome pathways (d).



medRxiv preprint doi: https://doi.org/10.1101/2022.04.19.22273587; this version posted April 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Figure S4. XGBoost model performance metrics as assessed by mean
absolute error. Mean absolute error (MAE) in XGBoost model performances in models predicting LAZ (a), WHZ (b), LAZ velocity (c) and WHZ velocity (d) stratified by maternal HIV status and age categories. Models were run using microbiome features alone (species or metagenomic pathways) and in combination with epidemiological variables.



velocity. Top ranked features in XGBoost model predictions of LAZ velocity (a) and

WHZ velocity (b) stratified by maternal HIV status. Only features from XGBoost

models with pseudo- $R^2 > 0$ are plotted.



growth. Top ranked features in XGBoost model predictions of WHZ velocity (a) and

WHZ in children born to HIV+ (b) and HIV- mothers (c). Only features from XGBoost

models with pseudo- $R^2 > 0$ are plotted.